
Veru (VERU) Stock Forecast & Price Target
Veru (VERU) Analyst Ratings
Bulls say
Veru Inc. is advancing its drug development program, particularly in metabolic diseases and oncology, with promising results from the Phase 2b QUALITY trial for Enobosarm, which has garnered positive topline results and secured a meeting with the FDA to discuss Phase 3 design. The company is expected to achieve profitability by 2029, driven by its focused market approach and successful trial outcomes, positioning it strategically within the micro-cap biopharma niche. While risks related to capital requirements and limited product diversification exist, management's relevant experience and the positive momentum in clinical trials contribute to a cautious yet optimistic outlook on Veru's future performance.
Bears say
Veru Inc. faces significant risks related to changing industry fundamentals, which could adversely affect expected revenues and earnings, particularly in a competitive biopharmaceutical environment. The company's reliance on key revenue-generating markets like the USA, alongside emerging competition and shifting investor sentiment, poses additional challenges to its market positioning. Furthermore, unforeseen developments concerning management practices or financial stability may further complicate the company's valuation outlook, heightening the negative sentiment regarding its stock.
This aggregate rating is based on analysts' research of Veru and is not a guaranteed prediction by Public.com or investment advice.
Veru (VERU) Analyst Forecast & Price Prediction
Start investing in Veru (VERU)
Order type
Buy in
Order amount
Est. shares
0 shares